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Introduction
Pneumocystis pneumonia (PCP) is a major health concern 
for immunocompromised individuals, whether due to HIV 
infection, chemotherapy or solid organ transplantation [1]. PCP 
is caused by the opportunistic fungal pathogen Pneumocystis 
jirovecii, a pathogen specific to humans, having no other 
reservoir [2]. Individuals suffering from PCP usually present 
with non-specific symptoms such as fever, cough, shortness of 
breath, and fatigue.  Sulfa drugs are the most common treatment 
for infection [3]. 
A rapid and accurate laboratory test is important for early 
diagnosis and treatment since any delay in treatment can 
significantly increase the risk of mortality. This organism has 
not been successfully cultured to date, so diagnosis depends 
on other laboratory methods. Traditionally, PCP has been 
diagnosed with the help of numerous staining methods or 
fluorescent antibody assays. Detection of nucleic acids from P. 
jirovecii in clinical samples has been evaluated numerous times, 
with certain authors making the case that molecular detection, 
such as quantitative PCR, should be the test of choice for PCP 
[4, 5].  While concerns about colonized versus infected patients 
have been raised, combining quantitative molecular detection 
with clinical judgment should reduce false positive results. 
We developed and evaluated a real-time PCR assay to detect 
P. jirovecii targeting mitochondrial large subunit ribosomal 
RNA gene (mtLSU rRNA) in lower respiratory tract specimens 
using the Luminex ARIES® instrument. The objective was to 
provide a rapid and sensitive test to health care practitioners 
serving immunocompromised patients in our  area, since 
sending these specimens to an out of state reference laboratory 
is expensive and takes at least one week for results. The mtLSU 
rRNA target was chosen because of the copy number and 
previous comparative studies [6].  The Luminex ARIES® is an 
open-platform instrument which uses MultiCode-RTx® base 
pairing (isoC:isoG) technology. This instrument was selected 
because it simplifies the extraction, amplification and detection 
process without affecting the robustness of diagnostic testing. 
Selective primers, labeled with fluorescent dyes, facilitate real 
time detection of both the mtLSU rRNA gene target for PCP and 
an internal control in a single-step. This assay enables rapid 
diagnosis with great sensitivity and specificity with little hands-
on time required.
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Abstract
Pneumocystis pneumonia (PCP) is an opportunistic infection caused by the fungus Pneumocystis 
jirovecii.  Infection with P. jirovecii can result in serious illness in patients with a weakened immune 
system, and can lead to death if it is not properly diagnosed and treated. Direct detection of P. 
jirovecii in lower respiratory tract specimens such as bronchoalveolar lavage (BAL) is preferred for 
rapid diagnosis, a laboratory service currently not available locally. We report here the development 
of a diagnostic real-time Polymerase Chain Reaction (PCR) assay using BAL specimens to detect P. 
jirovecii.  By targeting the multi-copy mitochondrial large subunit ribosomal RNA gene (mtLSU rRNA) 
of P. jirovecii, assay sensitivity is increased. Primer pairs were designed to include a fluorescent 
reporter dye-labeled primer with a unique MultiCode® base pair isoC on the 5’end and one unlabeled 
primer. The performance characteristics were determined on the Luminex ARIES® instrument, 
combining DNA extraction, amplification and detection into a one-step process. The cassette contains 
the reagents needed to perform all of the steps including extraction, purification, amplification, and 
detection, plus a sample processing control. Accuracy, precision, sensitivity, specificity and stability 
studies were conducted to validate the assay to meet CLIA requirements.  The analytical sensitivity 
was 89.1%, and the analytical specificity was 100%.  The assay could reliably detect 200 organisms/
mL, crossing thresholds (Ct) and melt temperatures (Tm) were consistent, and no cross-reactivity 
was observed with other pathogens known to cause respiratory infections.  The results demonstrated 
that these primers are specific to Pneumocystis jirovecii. The real-time PCR method using the 
ARIES® system allowed for rapid and sensitive detection of Pneumocystis pneumonia infections with 
P. jirovecii using clinical respiratory specimens.
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Materials and Methods
Specimens
Archived, de-identified PCP positive and negative clinical 
specimens were provided by Dr. Scott McClellan, University of 
Michigan, in order to set assay parameters.  These specimens 
were deemed exempt by the University of Michigan Institutional 
Review Board (S. McClellan, personal communication). Residual 
BAL specimens from consenting patients were used for analytical 
sensitivity, accuracy, precision, stability and specificity studies. 
Residual BAL specimens were determined to be negative for P. 
jirovecii using this PCR method prior to spiking with known 
concentrations of P. jirovecii DNA. Briefly, specimen processing 
was done in Bertin tubes (Precellys Lysis Kit, Reference number 
KT03961-1-006.2, Bertin Corp, Rockville, MD). First, 400 μl of 
BAL sample were added to the Bertin tube with 400 μL of AL 
buffer (QIAGEN Catalog number: 19075, Germantown, MS). 
The Bertin tube was placed on a vortex adaptor and shaken at 
10,000 rpm for 5 minutes to disrupt cells. After incubating at 
room temperature for 10 minutes, the tubes were centrifuged 
for 2 minutes at 14,000 rpm. Finally, 400 μL of supernatant was 
added to tubes containing 5 μL of carrier RNA, vortexed, then 
405 μL of sample with carrier RNA was used for the assay. 
Organisms
Fungal isolates were provided by Dr. Alan Junkins, Norton 
Healthcare, Louisville, KY. Eleven different fungi were spiked 
into negative BAL specimens and tested to assess cross-reactivity 
as follows: Candida dubliniensis, Candida parapsilosis, 
Candida glabrata, Candida krusei, Candida tropicalis, 
Cryptococcus neoformans, Saccharomyces cerevisiae, 
Histoplasma capsulatum (yeast form), Aspergillus fumigatus, 
Aspergillus versicolor and Aspergillus niger.  Streptococcus 
pneumoniae isolates from the University of Louisville Infectious 
Diseases Laboratory  were tested in the same way to assess 
cross-reactivity. A single colony was selected from freshly sub-
cultured plates using a sterile calibrated loop; the loop was used 
to inoculate BAL from patient specimens previously determined 
to be negative for PCP processed as described in the specimen 
section. College of American Pathologists (CAP) proficiency 
testing samples (archived IDR-A and IDR-B from 2018 events) 
containing numerous respiratory viruses and bacteria were used 
to assess cross-reactivity. For that purpose, 200 μL of proficiency 
test samples known to contain the following were spiked into 
negative BAL specimens: Coxsackie virus A9, Chlamydophila 
pneumoniae strain CWL 029, Influenza A California 07/2009 
(H1N1), Bordetella pertussis A639, Influenza B Massachusetts 
2/2012, Coronavirus NL63, Parainfluenza Type 2, RSV Type B 
CH93(18)-18,  Bordetella parapertussis A747, Parainfluenza 
virus Type 4, Echovirus 30 (E-30), Influenza B Strain 
Brisbane 60/2008, Parainfluenza Type 3, Adenovirus Type 21, 
Mycoplasma pneumoniae M129, Influenza A strain New York 
18/2009 (H1N1), and Human metapneumovirus B2. Also, 
previously characterized bacterial stocks from the University 
of Louisville Infectious Diseases Laboratory were tested to 
assess cross-reactivity [7]. Chlamydia pneumoniae, Legionella 
pneumophila, and Mycoplasma pneumoniae from each 
bacterial stock were spiked into BAL, using 160 μL of 1x105 CFU/
mL stock as input.
Control Materials 
Due to the limited number of clinical samples available 
for testing, recombinant P. jirovecii positive controls were 
purchased from Zeptometrix (NATtrol P. jirovecii Recombinant 
External Run Control, Catalog number 320679, Buffalo, NY) 
and EXACT Diagnostics (custom Pneumocystis jirovecii run 
control, Reference number PCPRC, Fort Worth, TX). 
Reagents
ARIES® MultiCode® DNA ReadyMix® tubes (Part number: 
3697, Luminex, Austin, TX) and ARIES® extraction cassettes 
(Part number: 50-10026, Luminex) were purchased ready to 
use. Carrier RNA (QIAGEN part number 1017647, Germantown, 
MD) was prepared as a 1 μg/μL solution in  AVE buffer (QIAGEN 
part number 1026956, Germantown, MD), aliquots were 
stored at -20°C.  Primer pairs, obtained from Integrated DNA 
Technologies Inc. (IDT, Coralville, IA), were designed to include 
a FAM reporter-labeled reverse primer with an isodC on the 
5’end, and a second unlabeled forward primer for P. jirovecii. 
The primer set was designed to amplify the mitochondria large 
subunit (mtLSU) rRNA from P. jirovecii based on a previous 
study [8]. Primer designs were evaluated by eye, then screened 
using IDT’s Oligo Analyzer software. Primer sequences are 
shown in Table 1. Each primer was used at a final concentration 
of 200 nM. Mouse Hepatitis Virus 2 control primers (MHV2, 
proprietary, Luminex Part Number 3803, Austin, TX) were 
used to amplify the Sample Processing Control (SPC; confirms 
extraction, amplification and detects inhibition). The SPC 
calibrator function allowed for calibration of detected melting 
temperatures (Tm) based on MHV2 amplification.
Primer Pool Preparation
The mtLSU rRNA forward and reverse lyophilized primers were 
dissolved in Tris-EDTA (TE buffer, Fisher Catalog #BP2473-1, 
Waltham, MA) to make a 100 μM stock solution of each primer. 
Further dilution of the 100 μM stock was done with molecular 
grade water to make 5 μM working stock.  To prepare the pooled 
primer mix, 100 μL of each 5 μM stock primer was combined 
with 100μL of MHV2 primer stock to make 300 μL total volume. 
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Table 1 Primers used for Luminex ARIES® P. jirovecii PCR assay.
PCR 
Pre-heat Temperature  95C 
Pre-heat hold time  0 sec 
Activation Temperature  95C 
Activation Time  120 sec 
Denature Temperature 95C 
Denature Time  5 sec 
Anneal Temperature  62C 
Anneal hold Time  7 sec 
Extension Temperature  72C 
Extension hold Time  14 sec 
Number of PCR steps repeat 3 (from Denature to Extend) 
Optical Read Location Extension 
Number of PCR cycles 45 
Melt  
Melt Temperature Step  0.5C 
Melt Start Temperature  60C 
Melt final Temperature  95C 
Melt Hold Time  2 sec 
Optical read location Melt hold time 
Table 2 PCR Thermal profile used for Luminex ARIES® P. jirovecii PCR 
assay.
Setting Conditions 
P. jirovecii  




















SPC= Sample Processing Control; RFU=Change in relative fluorescent units 
 
Table 3 P. jirovecii assay Amplification and Melt Curve Settings for ARIES®
The complete primer pool was then mixed well by vortexing, 
spun down and stored in 60 μL aliquots at -20°C.
ARIES® Cassette and Instrument Preparation
Six (6) µL of the mtLSU rRNA pooled primer mix were added 
to each MultiCode® DNA ReadyMix® tube, then attached to the 
ARIES® cassette.  ARIES® Cassettes (Part Number: 50-10026, 
Luminex, Austin, TX) contained the extraction reagents. Four 
hundred (400) µL of processed BAL sample were added to a 1.5 
mL micro centrifuge tube along with 5 µL of a 1 µg/mL carrier 
RNA stock. The tube was vortexed for five seconds prior to 
transferring the entire volume to the cassette and loaded onto 
the ARIES® instrument. The extraction, PCR reaction and result 
generation then proceeded automatically (PCR thermal cycle 
profile in Table 2). 
Sensitivity
For analytical sensitivity, the LOD was determined for the 
mtLSU rRNA target in BAL specimens that were negative by the 
Luminex ARIES® PCR assay described here.  The Zeptometrix 
PCP positive control (400 µL, 2x105 organisms per mL) was 
used as the initial dilution, followed by 6 ten-fold dilutions in 
the negative BAL specimen, then tested as described above. The 
LOD assay was conducted three times independently (Table 4). 
Accuracy
A panel of 24 (18 BAL, five sputum and one induced sputum) 
previously known positive and ten (eight BAL, one bronchial 
wash, and one sputum) known negative patient specimens 
provided by Dr. Scott McClellan (University of Michigan) were 
tested. Additionally, 17 spiked positive samples [PCP controls 
at varying dilutions: nine Zeptometrix controls at 2x105, 2x104, 
2x103, 2x102 organisms per mL, and eight Exact Diagnostics 
controls at 125,000 copies/mL, 12,500 copies/mL, 1250 copies/
mL and 125 copies/mL in BAL (Table 5)] and 14 negative 
blinded BAL samples were also tested by different technologists.
Precision
Reproducibility studies to determine precision were conducted 
using the Zeptometrix PCP control diluted 1:100 (2x103 
organisms/mL) in negative BAL samples. To demonstrate 
intra-assay and inter-assay precision, positive controls were 
tested for seven days and negative controls were tested for five 
days in duplicate, then for 10-15 days in singlet using different 
technologists.  Average and standard deviations were calculated 
using MS Excel (Table 6, A&B). 
Stability
Specimen stability studies were conducted by incubation of 
negative BAL samples spiked with known PCP Zeptometrix 
positive control diluted 1:100 (2x103 organisms/mL) and stored 
at 4°C, then assayed daily for 8 days (Table 7A). In addition, 
nine different known P. jirovecii positive clinical BAL samples 
were pooled and stored at 4°C, then assayed daily for 8 days 
(Table 7B).
Specificity
Eleven different fungi, eight different bacteria and 13 different 
viruses were spiked into negative BAL and tested in to assess 
cross-reactivity (Table 8). 
Data Analysis
Microsoft Excel® was used to calculate standard deviations 
for replicate experiments, while MedCalc Diagnostic Test 
Evaluation was used to determine analytic sensitivity and 
specificity [9]. The User Defined Protocol (UDP) module in 
the SYNCT® software was used to set assay parameters. The 
SYNCT® software was installed on an external computer for 
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P. jirovecii mtLSU 
rRNA 
Ct values (SD) 
P. jirovecii  
mtLSU rRNA 
Tm values (SD) 
SPC 
MHV2 
Ct values (SD) 
SPC 
MHV2 
Tm values( SD) 
2x105 25.97 (0.45) 77.90 (0.00) 34.23 (1.06) 77.40 (0.26) 
2x104 30.50 (0.82) 78.00 (0.00) 34.43 (0.80) 77.37 (0.32) 
2x103 33.87 (0.29) 78.03 (0.06) 33.73 (0.83) 77.40 (0.30) 
2x102 37.57 (1.04) 77.97 (0.15) 33.83 (1.12) 77.37 (0.32) 
2x101 ND ND 34.87 (1.37) 77.53 (0.31) 
2x100 38.10* 78.00* 35.03 (0.97) 77.40 (0.17) 
SPC= Sample Processing Control ;ND=Not Detected; SD= Standard Deviation 
*Positive result in one out of three runs. 
 
Table 5 Accuracy Results for the P. jirovecii PCR Assay
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Ct=Cycle threshold; Tm=Melt temperature; ND=Not Detected; 
SPC=Sample Processing Control; N/A=Not Applicable 
 






























30.7 31.4 33.8 34.10 32.7 33.6 32.8 
Positive 
Control 2 
32.7 31.9 32.1 31.6 32.2 34.5 33.7 




































33.6 37.2 37.8 37.0 35.3 N/A N/A 
Negative 
Control 2 
33.0 38 40.1 37.4 36.3 N/A N/A 











Table 6A Intra-assay Precision Studies for the P. jirovecii PCR Assay
Table 6B Inter-assay Precision Studies for the P. jirovecii PCR Assay
 
Sample Type P. jirovecii mtLSU 
rRNA Ct value 
P. jirovecii Tm 
value 
SPC Ct value SPC Tm value 
Positive Control 
(n=15) 
32.98 (0.91) 77.98 (0.12) 35.02 (1.75) 76.99 (0.32) 
Negative Control 
(n=10) 
ND ND 36.12 (1.72) 77.28 (0.36) 
Ct=Cycle threshold; Tm=Melt temperature; ND=Not Detected;  






mtLSU rRNA Ct 
Average (SD) 
P. jirovecii 
mtLSU rRNA Tm 
Average (SD) 
SPC Ct Average 
(SD) 
SPC Tm Average 
(SD) 
BAL 33.24 (0.57) 78.04 (0.09) 34.29 (1.34) 76.95 (0.24) 
 
Ct=Cycle threshold; Tm=Melt temperature; ND=Not Detected; 
SPC=Sample Processing Control 
 
 
Table 7A P. jirovecii Stability Studies using positive control spiked into 
negative BAL











SPC Ct Average 
(SD) 
SPC Tm Average 
(SD) 
BAL 34.46 (0.50) 77.93 (0.08) 37.86 (2.20) 77.56 (0.13) 
 
Ct=Cycle threshold; Tm=Melt temperature; ND=Not Detected; 
SPC=Sample Processing Control 
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detailed data analysis and editing of Ct and Tm cutoff values. 
After completing data analysis and PCR assay validation, the 
Ct and Tm cut off values were set and locked in the SYNCT® 
software assay file. Next, the assay file was loaded on the ARIES® 
instrument for subsequent diagnostic laboratory testing (Table 
3). In order for a specimen to be called positive for P. jirovecii, 
the following conditions had to be met: 
1. The SPC for any negative specimen must have a valid Ct 
value and Tm to exclude sample inhibition.
2. The specimen must have Ct and Tm values in the 
established range for the target organism P. jirovecii.
Results
Using a combination of positive and negative patient specimens, 
and spiked known concentrations of recombinant external 
positive controls, the performance characteristics of the PCR 
assay on the ARIES® system were established. The results of 
this study were highly reproducible, as demonstrated by testing 
positive and negative controls with different technologists 
on different days. We obtained consistent results with low 
standard deviations (Tables 4, 6A&B and 7A&B).  Analytical 
sensitivity for the P. jirovecii assay was 89.1% (95% CI 76.43-
96.38%), while analytical specificity was 100% (95% CI 87.23 
-100), (Table 5).  Stability studies were performed using 
positive control material spiked into negative BAL and pooled 
P. jirovecii clinical positive BAL samples, stored at 2-8°C for 
eight days and tested daily for 8 days.  Results showed that DNA 
was detected by the PCR assay under these storage conditions 
(Table 7A and B).  Finally, a variety of fungi, bacteria, and 
viruses that can cause respiratory infections were tested to 
establish specificity. There was no cross-reactivity observed 
with the P. jirovecii mtLSU rRNA primers using 32 different 
organisms (Table 8).  By including the SPC, any inhibition of 
PCR would have been detected, and none was observed during 
these studies (Table 8).
The assay could reliably detect 3000 copies of mtLSU rRNA 
that equated to 200 organisms/mL of  P. jirovecii (Table 4) in 
respiratory specimens.  It is important to note that P. jirovecii is 
estimated to have 15 copies of the mtLSU rRNA gene/organism 
[10], allowing for more sensitive detection by PCR. 
Discussion
Quality laboratory results are dependent on proper specimen 
collection, transport, storage and processing procedures, as well 
as adherence to good molecular laboratory techniques to avoid 
false positive and false negative results. As with any laboratory 
test, regardless of the method used to diagnose Pneumocystis 
pneumonia, clinical judgment in light of patient presentation 
and history are the ultimate deciding factors for patient 
treatment and management [11]. 
The strengths of this study include the demonstration of the 
precision, limit of detection using quantitated target DNA and 
demonstration of specificity.  In addition, the ability to adapt the 
PCR assay to the Luminex ARIES® platform so that extraction, 
amplification and detection occur in a closed system reduces 
potential cross-contamination.  Some limitations of this study 
include the small number of clinical samples available for testing 
and the use of spiked BAL samples to mimic clinical samples. 
Due to a limited number of available clinical specimens, 
stability studies were conducted with positive control material 
in the form of plasmids as well as with pooled positive clinical 
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Candida dubliniensis BAL 32.4 76.6 Negative  
Candida parapsilosis BAL 33.9 76.9 Negative  
Candida glabrata BAL 34.9 76.9 Negative  
Candida krusei BAL 33.9 76.9 Negative  
Candida tropicalis BAL 35.1 76.9 Negative  
Cryptococcus neoformans BAL 33.3 77.1 Negative  
Saccharomyces cerevisiae BAL 32.8 77.7 Negative  
Histoplasma capsulatum (yeast form) BAL 33.9 76.9 Negative  
Aspergillus fumigatus BAL 34.7 76.6 Negative  
Aspergillus versicolor BAL 36.1 76.4 Negative  
Aspergillus niger BAL 32.1 76.9 Negative  
Bacteria 
Chlamydophila pneumoniae strain CWL 029 BAL 36.5 77 Negative  
Bordetella pertussis A639 BAL 37.5 77.1 Negative  
Bordetella parapertussis A747  BAL 37.6 76.8 Negative  
Mycoplasma pneumoniae strain M129 BAL 39.4 76.9 Negative  
Chlamydia pneumoniae BAL 39.3 76.9 Negative  
Legionella pneumophila BAL 38.2 76.7 Negative  
Mycoplasma pneumoniae BAL 36.9 76.9 Negative  
Streptococcus pneumoniae BAL 39.1 77.7 Negative  
Viruses 
Enterovirus Coxsackie A9  BAL 36.5 77 Negative  
Influenza A strain California 07/2009 (H1N1)  BAL 37.5 77.1 Negative  
Influenza B Massachusetts 2/2012  BAL 35.9 76.9 Negative  
Coronavirus NL63 BAL 35.9 76.9 Negative  
Parainfluenza Type 2  BAL 37.6 77 Negative  
RSV Type B CH93 (18) BAL 37.6 77 Negative  
Parainfluenza virus Type 4 BAL 37.6 76.8 Negative  
Echovirus 30 (E-30) BAL 36.7 77.1 Negative  
Influenza B Strain Brisbane 60/2008  BAL 39.5 76.9 Negative  
Parainfluenza Type 3 BAL 39.5 76.9 Negative  
Adenovirus strain  Type 21  BAL 39.4 76.9 Negative  
Influenza A strain New York 18/2009 (H1N1)  BAL 39.7 76.9 Negative  
Human metapneumovirus strain B2 BAL 39.7 76.9 Negative  
 
Table 8 Specificity Studies for the P. jirovecii PCR assay
Figure 1A Negative Control Result: Sample data from ARIES® instrument 
with a negative control illustrating the amplification curve (Ct) and melt 
temperature (Tm) for the internal control (SPC).
Figure 1B Positive Control Result: Sample data from ARIES® instrument 
with a positive control illustrating the amplification curve (Ct) and melt 
temperature (Tm) for P. jirovecii.
ULJRI Vol 3, (1) 2019
specimens.  Comparison to a “gold standard” assay was also 
problematic.  Numerous publications regarding PCR detection 
of P. jirovecii have used a wide variety of gene targets, methods, 
instruments, and limits of detection reporting units (i.e. trophic 
form equivalents [12], plasmid copy/uL [13], DNA copy/uL 
[11] or cysts/amplification [14], making direct comparisons 
challenging [15]).   
A valid concern with PCP molecular detection assays is that this 
PCR assay could detect colonized patients as well as patients 
with infections.  While this PCR assay was used in a qualitative 
manner, the Ct values provided some indication of organism 
load when P. jirovecii was detected [12, 13]. Example instrument 
results are provided in Figures 1A and 1B.   Based on a likely 
human-to-human transmission route [16-18], detecting 
colonization may be relevant in certain situations.  Setting a 
cutoff for colonization may not be practical for all situations, 
however, such as fungal load variability in HIV-infected versus 
non-infected immunosuppressed patients, or pediatric patients 
versus adult patients [8, 11, 19].   While microscopic analysis 
remains a valid laboratory method for determining infection 
with these organisms, it requires a high level of technical 
expertise. It also lacks the sensitivity of  molecular diagnostics 
by an estimated factor of 100 [14], thus supporting the need for 
molecular diagnostic assays for detection of P. jirovecii. 
Exploration of quantitative PCR assays for P. jirovecii, adding 
other targets (e.g. drug resistance markers or virulence factors), 
and identifying other high copy number genes such as the 
mitochondrial smaller subunit (mtSSU) rRNA [10] are future 
goals to make this assay more sensitive and useful to clinicians. 
In particular, drug resistance markers are of great interest in 
an era of antibiotic stewardship initiatives.  A study conducted 
in Chile observed a high prevalence of mutations in the 
dihydropteroate synthase (DHPS) gene in P. jirovecii infected 
patients, despite a lack of previous exposure to trimethoprim-
sulfamethoxazole or dapsone [18].  This study suggested a role 
for person-to-person transmission.  The presence of the DHPS 
mutation correlated with twice longer duration of mechanical 
ventilation in this hospitalized group of 56 patients [18], 
indicating an important area for future study.
The benefits of the ARIES® P. jirovecii assay include minimal 
hands-on time for technologists, one step specimen processing 
with a robust internal sample processing control, all within 
a closed system.  Results are available within two hours while 
providing rapid, specific and sensitive results for health care 
providers. The ability to tailor PCR assays to the local health 
care community, and to add new targets with guidance from 
Luminex technical support, adds a high degree of flexibility 
for future P. jirovecii assay improvements. Based on the 
performance characteristics established by our laboratory, the 
ARIES® real-time PCR assay meets the CLIA requirements for 
diagnostic testing using BAL specimens from patients suspected 
of having PCP.  Having the real-time PCR assay available to 
health care providers managing immunocompromised patients 
in our community will provide results within 24 hours of receipt, 
leading to better patient management.
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